S&P 500   4,452.12 (-0.08%)
DOW   34,960.28 (+0.47%)
QQQ   371.04 (-0.61%)
AAPL   145.25 (-1.14%)
MSFT   295.26 (-1.37%)
FB   351.22 (-0.49%)
GOOGL   2,826.63 (-0.62%)
TSLA   788.67 (+1.84%)
AMZN   3,363.66 (-1.81%)
NVDA   216.32 (-2.03%)
BABA   147.25 (+1.50%)
NIO   35.95 (+1.61%)
CGC   14.46 (+3.95%)
GE   105.65 (+1.78%)
MU   75.20 (+1.55%)
AMD   107.39 (+1.50%)
T   27.60 (+1.73%)
F   14.12 (+2.47%)
ACB   6.16 (+3.53%)
DIS   178.37 (+1.35%)
PFE   44.04 (+0.23%)
BA   226.21 (+2.18%)
BAC   43.17 (+2.44%)
S&P 500   4,452.12 (-0.08%)
DOW   34,960.28 (+0.47%)
QQQ   371.04 (-0.61%)
AAPL   145.25 (-1.14%)
MSFT   295.26 (-1.37%)
FB   351.22 (-0.49%)
GOOGL   2,826.63 (-0.62%)
TSLA   788.67 (+1.84%)
AMZN   3,363.66 (-1.81%)
NVDA   216.32 (-2.03%)
BABA   147.25 (+1.50%)
NIO   35.95 (+1.61%)
CGC   14.46 (+3.95%)
GE   105.65 (+1.78%)
MU   75.20 (+1.55%)
AMD   107.39 (+1.50%)
T   27.60 (+1.73%)
F   14.12 (+2.47%)
ACB   6.16 (+3.53%)
DIS   178.37 (+1.35%)
PFE   44.04 (+0.23%)
BA   226.21 (+2.18%)
BAC   43.17 (+2.44%)
S&P 500   4,452.12 (-0.08%)
DOW   34,960.28 (+0.47%)
QQQ   371.04 (-0.61%)
AAPL   145.25 (-1.14%)
MSFT   295.26 (-1.37%)
FB   351.22 (-0.49%)
GOOGL   2,826.63 (-0.62%)
TSLA   788.67 (+1.84%)
AMZN   3,363.66 (-1.81%)
NVDA   216.32 (-2.03%)
BABA   147.25 (+1.50%)
NIO   35.95 (+1.61%)
CGC   14.46 (+3.95%)
GE   105.65 (+1.78%)
MU   75.20 (+1.55%)
AMD   107.39 (+1.50%)
T   27.60 (+1.73%)
F   14.12 (+2.47%)
ACB   6.16 (+3.53%)
DIS   178.37 (+1.35%)
PFE   44.04 (+0.23%)
BA   226.21 (+2.18%)
BAC   43.17 (+2.44%)
S&P 500   4,452.12 (-0.08%)
DOW   34,960.28 (+0.47%)
QQQ   371.04 (-0.61%)
AAPL   145.25 (-1.14%)
MSFT   295.26 (-1.37%)
FB   351.22 (-0.49%)
GOOGL   2,826.63 (-0.62%)
TSLA   788.67 (+1.84%)
AMZN   3,363.66 (-1.81%)
NVDA   216.32 (-2.03%)
BABA   147.25 (+1.50%)
NIO   35.95 (+1.61%)
CGC   14.46 (+3.95%)
GE   105.65 (+1.78%)
MU   75.20 (+1.55%)
AMD   107.39 (+1.50%)
T   27.60 (+1.73%)
F   14.12 (+2.47%)
ACB   6.16 (+3.53%)
DIS   178.37 (+1.35%)
PFE   44.04 (+0.23%)
BA   226.21 (+2.18%)
BAC   43.17 (+2.44%)
NYSE:HRC

Hill-Rom Stock Forecast, Price & News

$149.62
-0.38 (-0.25 %)
(As of 09/27/2021 11:08 AM ET)
Add
Compare
Today's Range
$149.60
$150.08
50-Day Range
$115.20
$151.88
52-Week Range
$80.76
$152.37
Volume8,321 shs
Average Volume616,991 shs
Market Capitalization$9.85 billion
P/E Ratio42.15
Dividend Yield0.64%
Beta0.6
30 days | 90 days | 365 days | Advanced Chart
Receive HRC News and Ratings via Email

Sign-up to receive the latest news and ratings for Hill-Rom and its competitors with MarketBeat's FREE daily newsletter.


Hill-Rom logo

About Hill-Rom

Hill-Rom Holdings, Inc. operates as a medical technology company. The firm focuses on patient care solutions that improve clinical and economic outcomes. It operates through the following segments: Patient Support System, Front Line Care and Surgical Solutions. The Patient Support Systems segment provides bed frames and surfaces, mobility and clinical workflow solutions. The Front Line Care segment offers respiratory care products and sells medical diagnostic equipment and a diversified portfolio of devices. The Surgical Solutions segment supplies surgical products including tables, lights, pendants, positioning devices, various other surgical products and accessories. The company was founded by William A. Hillenbrand on August 7, 1969 and is headquartered in Chicago, IL.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

2.05 out of 5 stars

Medical Sector

505th out of 1,352 stocks

Surgical & Medical Instruments Industry

50th out of 123 stocks

Analyst Opinion: 1.1Community Rank: 4.4Dividend Strength: 1.7Insider Behavior: 2.5Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Hill-Rom (NYSE:HRC) Frequently Asked Questions

Is Hill-Rom a buy right now?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Hill-Rom in the last year. There are currently 5 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" Hill-Rom stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in HRC, but not buy additional shares or sell existing shares.
View analyst ratings for Hill-Rom
or view top-rated stocks.

What stocks does MarketBeat like better than Hill-Rom?

Wall Street analysts have given Hill-Rom a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Hill-Rom wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Hill-Rom?

Hill-Rom saw a decline in short interest during the month of August. As of August 31st, there was short interest totaling 765,700 shares, a decline of 20.0% from the August 15th total of 957,400 shares. Based on an average trading volume of 822,000 shares, the short-interest ratio is presently 0.9 days. Currently, 1.2% of the shares of the company are sold short.
View Hill-Rom's Short Interest
.

When is Hill-Rom's next earnings date?

Hill-Rom is scheduled to release its next quarterly earnings announcement on Friday, November 5th 2021.
View our earnings forecast for Hill-Rom
.

How were Hill-Rom's earnings last quarter?

Hill-Rom Holdings, Inc. (NYSE:HRC) announced its quarterly earnings data on Friday, July, 30th. The medical technology company reported $1.38 earnings per share for the quarter, beating the consensus estimate of $1.35 by $0.03. The medical technology company had revenue of $717.70 million for the quarter, compared to the consensus estimate of $708.33 million. Hill-Rom had a trailing twelve-month return on equity of 21.74% and a net margin of 8.12%. The company's quarterly revenue was down 6.5% compared to the same quarter last year. During the same quarter in the previous year, the business posted $1.95 earnings per share.
View Hill-Rom's earnings history
.

How has Hill-Rom's stock price been impacted by COVID-19 (Coronavirus)?

Hill-Rom's stock was trading at $89.15 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, HRC shares have increased by 68.0% and is now trading at $149.75.
View which stocks have been most impacted by COVID-19
.

How often does Hill-Rom pay dividends? What is the dividend yield for Hill-Rom?

Hill-Rom declared a quarterly dividend on Thursday, July 8th. Shareholders of record on Friday, September 17th will be paid a dividend of $0.24 per share on Thursday, September 30th. This represents a $0.96 annualized dividend and a dividend yield of 0.64%. The ex-dividend date of this dividend is Thursday, September 16th.
View Hill-Rom's dividend history
.

Is Hill-Rom a good dividend stock?

Hill-Rom pays an annual dividend of $0.96 per share and currently has a dividend yield of 0.64%. Hill-Rom does not yet have a strong track record of dividend growth. The dividend payout ratio of Hill-Rom is 17.36%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, Hill-Rom will have a dividend payout ratio of 14.98% next year. This indicates that Hill-Rom will be able to sustain or increase its dividend.
View Hill-Rom's dividend history.

What guidance has Hill-Rom issued on next quarter's earnings?

Hill-Rom updated its FY 2021 earnings guidance on Friday, August, 6th. The company provided earnings per share guidance of $6.080-$6.120 for the period, compared to the Thomson Reuters consensus estimate of $6.060. The company issued revenue guidance of $2.97 billion-$3.00 billion, compared to the consensus revenue estimate of $2.94 billion.

What price target have analysts set for HRC?

6 analysts have issued twelve-month price objectives for Hill-Rom's stock. Their forecasts range from $117.00 to $156.00. On average, they expect Hill-Rom's share price to reach $137.67 in the next twelve months. This suggests that the stock has a possible downside of 8.1%.
View analysts' price targets for Hill-Rom
or view top-rated stocks among Wall Street analysts.

Who are Hill-Rom's key executives?

Hill-Rom's management team includes the following people:
  • John P. Groetelaars, President, Chief Executive Officer & Director
  • Tim Lawrence, Senior Vice President-Operations
  • Barbara W. Bodem, Chief Financial Officer & Senior Vice President
  • Brian L. Lawrence, Chief Technology Officer & SVP-Innovation
  • Ilana Shulman, Chief Compliance Officer

What is John P. Groetelaars' approval rating as Hill-Rom's CEO?

54 employees have rated Hill-Rom CEO John P. Groetelaars on Glassdoor.com. John P. Groetelaars has an approval rating of 82% among Hill-Rom's employees.

What other stocks do shareholders of Hill-Rom own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Hill-Rom investors own include Steel Dynamics (STLD), The Walt Disney (DIS), NVIDIA (NVDA), Square (SQ), PayPal (PYPL), salesforce.com (CRM), CVS Health (CVS), Micron Technology (MU), AbbVie (ABBV) and Bank of America (BAC).

What is Hill-Rom's stock symbol?

Hill-Rom trades on the New York Stock Exchange (NYSE) under the ticker symbol "HRC."

Who are Hill-Rom's major shareholders?

Hill-Rom's stock is owned by a number of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (10.20%), BlackRock Inc. (9.68%), Victory Capital Management Inc. (5.49%), UBS Asset Management Americas Inc. (2.94%), State Street Corp (2.70%) and Cooke & Bieler LP (2.69%). Company insiders that own Hill-Rom stock include Amy M Dodrill, Andreas G Frank, Deborah Rasin, Jeffrey F Dimodica, Mary Kay Ladone and Paul Sherwood Johnson.
View institutional ownership trends for Hill-Rom
.

Which major investors are selling Hill-Rom stock?

HRC stock was sold by a variety of institutional investors in the last quarter, including American Century Companies Inc., UBS Asset Management Americas Inc., BlackRock Inc., Natixis, LSV Asset Management, FMR LLC, Invesco Ltd., and Dimensional Fund Advisors LP. Company insiders that have sold Hill-Rom company stock in the last year include Andreas G Frank, Deborah Rasin, Jeffrey F Dimodica, Mary Kay Ladone, and Paul Sherwood Johnson.
View insider buying and selling activity for Hill-Rom
or view top insider-selling stocks.

Which major investors are buying Hill-Rom stock?

HRC stock was bought by a variety of institutional investors in the last quarter, including Panagora Asset Management Inc., Balyasny Asset Management LLC, Cooke & Bieler LP, Victory Capital Management Inc., Allianz Asset Management GmbH, Northern Trust Corp, Amundi, and Goldman Sachs Group Inc..
View insider buying and selling activity for Hill-Rom
or or view top insider-buying stocks.

How do I buy shares of Hill-Rom?

Shares of HRC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Hill-Rom's stock price today?

One share of HRC stock can currently be purchased for approximately $149.75.

How much money does Hill-Rom make?

Hill-Rom has a market capitalization of $9.86 billion and generates $2.88 billion in revenue each year. The medical technology company earns $223 million in net income (profit) each year or $5.53 on an earnings per share basis.

How many employees does Hill-Rom have?

Hill-Rom employs 10,000 workers across the globe.

What is Hill-Rom's official website?

The official website for Hill-Rom is www.hill-rom.com.

Where are Hill-Rom's headquarters?

How can I contact Hill-Rom?

Hill-Rom's mailing address is 130 East Randolph Street Suite 1000, Chicago IL, 60601. The medical technology company can be reached via phone at (312) 819-7200 or via email at [email protected].


This page was last updated on 9/27/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.